logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2019 — Niraparib effective in newly diagnosed advanced ovarian cancer

Should first-line platinum-based chemotherapy be followed by the PARP inhibitor niraparib in advanced ovarian cancer?